Nonmedical factors in treatment selection

Urologic Clinics of North America

Volumn 30, Issue 2, 2003, Pages 331-335

  Brawley, Otis W ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HORMONE;

AGE DISTRIBUTION; ALTERNATIVE MEDICINE; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CLINICAL PRACTICE; GEOGRAPHY; HUMAN; PATIENT CARE; PATIENT EDUCATION; PATIENT SELECTION; PERCEPTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RACE; REVIEW; SOCIOECONOMICS; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 0037408060     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0094-0143(02)00186-6     Document Type: Review

References (31)

1. Adolfsson J. [Treatment of localized prostatic cancer-different alternatives. Patients with localized prostatic cancer must actively participate in the choice of therapy.] Lakartidningen 2000;97:3870-4.
2. Walsh PC. Surgery and the reduction of mortality from prostate cancer. N Engl J Med 2002;347:839-40.
3. Middleton RG, Thompson IM, Austenfeld MS, et al. Prostate Cancer Clinical Guidelines Panel Summary report on the management of clinically localized prostate cancer. The American Urological Association. J Urol 1995;154:2144-8.
4. Montie JE. Counseling the patient with localized prostate cancer. Urology 1994;43:36-40.
5. Thompson IM. Counseling patients with newly diagnosed prostate cancer. Oncology (Huntingt) 2000;14:119-26, 131.
6. Mettlin C. Changes in patterns of prostate cancer care in the United States: results of American College of Surgeons Commission on Cancer studies, 1974-1993. Prostate 1997;32:221-6.
7. Stanford JL, Stephenson RA, Coyle LM, et al. Prostate Cancer Trends 1973-1995. SEER Program, National Cancer Institute. NIH Pub. No. 99-4543. Bethesda: National Cancer Institute; 1999.
8. Mettlin CJ, Murphy GP, Cunningham MP, et al. The National Cancer Data Base report on race, age, and region variations in prostate cancer treatment. Cancer 1997;80:1261-6.
9. Harlan LC, Potosky A, Gilliland FD, et al. Factors associated with initial therapy for clinically localized prostate cancer: prostate cancer outcomes study. J Natl Cancer Inst 2001;93:1864-71.
10. Bubolz T, Wasson JH, Lu-Yao G, et al. Treatments for prostate cancer in older men: 1984-1997. Urology 2001;58:977-82.
11. Lu-Yao GL, Greenberg ER. Changes in prostate cancer incidence and treatment in USA. Lancet 1994;343:251-4.
12. Harlan L, Brawley O, Pommerenke F, et al. Geographic, age, and racial variation in the treatment of local/regional carcinoma of the prostate. J Clin Oncol 1995;13:93-100.
13. Thomson MA, O'Brien MA, Oxman AD, Haynes RB, et al. Local opinion leaders: effects on professional practice and health care outcomes. Available at: Cochrane Database Syst Rev CD000125. Date accessed: August 13, 2002.
14. Brawley OW. Prostate carcinoma incidence and patient mortality: the effects of screening and early detection. Cancer 1997;80:1857-63.
15. Desch CE, Penberthy L, Newschaffer CJ, et al. Factors that determine the treatment for local and regional prostate cancer. Med Care 1996;34:152-62.
16. Mettlin C, Jones GW, Murphy GP. Trends in prostate cancer care in the United States, 1974-1990: observations from the patient care evaluation studies of the American College of Surgeons Commission on Cancer. CA Cancer J Clin 1993;43:83-91.
17. Morris CR, Snipes KP, Schlag R, et al. Sociodemographic factors associated with prostatectomy utilization and concordance with the physician data query for prostate cancer (United States). Cancer Causes Control 1999;10:503-11.
18. Polednak AP. Prostate cancer treatment in black and white men: the need to consider both stage at diagnosis and socioeconomic status. J Natl Med Assoc 1998;90:101-4.
19. Polednak AP, Flannery JT. Black versus white racial differences in clinical stage at diagnosis and treatment of prostatic cancer in Connecticut. Cancer 1992;70:2152-8.
20. Klabunde CN, Potosky AL, Harlan LC, et al. Trends and black/white differences in treatment for nonmetastatic prostate cancer. Med Care 1998;36:1337-48.
21. Schapira MM, McAuliffe TL, Nattinger AB. Treatment of localized prostate cancer in African American compared with Caucasian men. Less use of aggressive therapy for comparable disease. Med Care 1995;33:1079-88.
22. Demark-Wahnefried W, Schildkraut JM, Iselin CE, et al. Treatment options, selection, and satisfaction among African American and white men with prostate carcinoma in North Carolina. Cancer 1998;83:320-30.
23. Brawley OW. The study of untreated syphilis in the Negro male. Int J Radiat Oncol Biol Phys 1998;40:5-8.
24. Kohan AD, Armenakas NA, Fracchia JA. The perioperative charge equivalence of interstitial brachytherapy and radical prostatectomy with 1year followup. J Urol 2000;163:511-4.
25. Perez CA. The cost-benefit of 3D conformal radiation therapy compared with conventional techniques for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 1999;45:1103-4.
26. Brandeis J, Pashos CL, Henning JM, et al. Racial differences in the cost of treating men with earlystage prostate cancer. J Am Geriatr Soc 2001;49:297-303.
27. Fowler Jr FJ, Barry MJ, Lu-Yao G, et al. Outcomes of external-beam radiation therapy for prostate cancer: a study of Medicare beneficiaries in three surveillance, epidemiology, and end results areas. J Clin Oncol 1996;14:2258-65.
28. Patterson RE, Neuhouser ML, Hedderson MM, et al. Types of alternative medicine used by patients with breast, colon, or prostate cancer: predictors, motives, and costs. J Altern Complement Med 2002;8:477-85.
29. Diefenbach MA, Dorsey J, Uzzo RG, et al. Decision-making strategies for patients with localized prostate cancer. Semin Urol Oncol 2002;20:55-62.
30. Mazur DJ, Merz JF. How older patients' treatment preferences are influenced by disclosures about therapeutic uncertainty: surgery versus expectant management for localized prostate cancer. J Am Geriatr Soc 1996;44:934-7.
31. Mazur DJ, Hickam DH, Mazur MD. How patients' preferences for risk information influence treatment choice in a case of high risk and high therapeutic uncertainty: asymptomatic localized prostate cancer. Med Decis Making 1999;19:394-8.